Statin treatment and reduced risk of pneumonia in patients with diabetes

van de Garde, E. M. W.; Hak, E.; Souverein, P. C.; Hoes, A. W.; van den Bosch, J. M. M.; Leufkens, H. G. M.
November 2006
Thorax;Nov2006, Vol. 61 Issue 11, p957
Academic Journal
Background: Recent prognostic studies have shown that previous treatment with statins is associated with a better outcome in patients admitted to hospital with pneumonia. Because of an increased risk of pneumonia in patients with diabetes, we assessed the effects of statin use on the occurrence of pneumonia in adult diabetic patients. Methods: All patients with a diagnosis of diabetes (types 1 and 2) enlisted in the UK General Practice Research Database between 1 June 1987 and 21 January 2001 were included. A case-control study was performed with cases defined as patients with a first recorded diagnosis of pneumonia. For each case up to four controls were matched by age, sex, practice, and index date. Patients were classified as current users when the index date was between the start and end date of statin treatment. Conditional multiple logistic regression analysis was used to estimate the strength of the association between statin treatment and the occurrence of pneumonia. Results: Statins were used in 1.1% of 4719 cases and in 2.1% of 15322 matched controls (crude odds ratio (OR) 0.51, 95% CI 0.37 to 0.68). After adjusting for potential confounders, treatment with statins was associated with a significant reduction in the risk of pneumonia (adjusted OR 0.49, 95% CI 0.35 to 0.69). The association was consistent among relevant subgroups (cardiovascular diseases, pulmonary diseases) and independent of the use of other prescription drugs. Conclusions: The use of statins is associated with a considerable reduction in the risk of pneumonia in diabetic patients. In addition to lowering the risk of cardiovascular disease, statins may be useful in preventing respiratory infections.


Related Articles

  • Statins and the Risk of Diabetes. Elliott, William T. // Infectious Disease Alert;Apr2012 Pharmacology, p1 

    The article presents information on a study which examined the potential of statin medication to increase the risk of diabetes mellitus (DM) in the elderly, postmenopausal women, and Asians.

  • Risk of developing diabetes with higher potency statins.  // Reactions Weekly;Jun2014, Vol. 1505 Issue 1, p4 

    The article reports on the result of the evaluation by drug safety research center Canadian Network for Observational Drug Effect Studies which showed small increase in the risk of new onset diabetes in recipients of higher potency over lower potency statins.

  • Link between statin use and diabetes risk dose dependent.  // Reactions Weekly;7/2/2011, Issue 1358, p3 

    The article reports on the results of a study on the impact of statin on patients with diabetes that was conducted by researcher Naveed Sattar and colleagues and published in the February 2010 issue of the journal "The Lancet."

  • FROM BMJ JOURNALS: Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases. Corrao, G.; Zambon, A.; Bertugrave;, L.; Botteri, E.; Leoni, O.; Contiero, P. // Heart;Apr2005, Vol. 91 Issue 4, p560 

    Study objective: Although lipid lowering drugs are effective in preventing morbidity and mortality from cardiovascular events, the extent of theft adverse effects is not clear. This study explored the association between prescription of lipid lowering drugs and the risk of peripheral neuropathy....

  • Rosuvastatin 'safe as other statins'.  // GP: General Practitioner;10/29/2004, p4 

    The article focuses on a review of safety data which highlights that patients taking rosuvastatin 5-40 milligrams are no more likely to suffer adverse events than those on other statins. The study also showed that the adverse event profile of rosuvastatin was similar to that of atorvastatin,...

  • Communicating risk using absolute risk reduction or prolongation of life formats: cluster-randomised trial in general practice. Harmsen, Charlotte Gry; Kristiansen, Ivar Sønbø; Larsen, Pia Veldt; Nexøe, Jørgen; Støvring, Henrik; Gyrd-Hansen, Dorte; Nielsen, Jesper Bo; Edwards, Adrian; Jarbøl, Dorte Ejg // British Journal of General Practice;Apr2014, Vol. 64 Issue 621, pe199 

    Background: It is important that patients are well-informed about risks and benefits of therapies to help them decide whether to accept medical therapy. Different numerical formats can be used in risk communication but It remains unclear how the different formats affect decisions...

  • OTC statins assessment poor.  // Pulse;10/19/2006, Vol. 66 Issue 39, p15 

    The article reports on the evaluation of the criteria for over-the-counter (OTC) statins which is employed by pharmacists to assess patients in Great Britain. According to the researchers, OTC statins assessment are inaccurate and may lead to undertreatment of high-risk individuals. Moreover,...

  • A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death. Mesgarpour, Bita; Gouya, Ghazaleh; Herkner, Harald; Reichardt, Berthold; Wolzt, Michael // Lipids in Health & Disease;10/24/2015, Vol. 14, p1 

    Background: Clarithromycin, known as a potent inhibitor of the cytochrome P450 isoenzyme CYP3A, may increase the plasma concentration of statins metabolized by this pathway; therefore, increase the risk of interaction with statins in reference to pharmacokinetic studies. This study aimed to...

  • Statins in patients with cancer.  // OB/GYN Clinical Alert;Jan2013 Pharmacology Watch, p2 

    The article discusses a study, which evaluated cancer patients between 1995 and 2007 and highlights that patients diagnosed with cancer and taking statin, a drug used to cure cancer, are likely to live more than those who are not taking it.


Read the Article


Sign out of this library

Other Topics